Roche
Roche blockbuster immunotherapy Tecentriq outclassed by chemo in latest trial
May 10, 2017Research and Development, Sales and Marketing Roche, tecentriq
It has been revealed that Roche’s immuno-oncology drug Tecentriq (atezolizumab) has failed to hit its primary endpoint in a follow-up …
WHO aims to increase uptake of biosimilars in poorer countries
May 4, 2017Medical Communications, Research and Development Cancer, Roche, WHO, biosimilars
The WHO has announced that it will launch a project to prequalify biosimilar medicines for the treatment of certain cancers. …
Roche denies its acne treatment led to suicide of 21 year old
May 4, 2017Medical Communications, Sales and Marketing Roaccutane, Roche
Last month, Luke Reeves took his own life at the age of just 21. Prior to his death, he had …
‘World Hemophilia Day’ marked by release of data
April 20, 2017Medical Communications, Research and Development Roche, Shire, haemophilia
‘World Hemophilia Day’ occurred on 17 April and the day was marked by the release of data from two companies …
Roche’s drug scores expanded FDA indication in advanced bladder cancer
April 18, 2017Manufacturing and Production, Sales and Marketing Genentech, Roche, tecentriq
Roche’s Genentech has revealed that its immunotherapy drug Tecentriq (atezolizumab) is now enjoying an expanded indication in the US after …
Roche’s lung cancer drug beats Pfizer rival in study
April 10, 2017Research and Development, Sales and Marketing Alecensa, Roche
Roche has announced that its drug Alecensa (alectinib) succeeded in meeting its primary endpoint in a Phase 3 trial assessing …
First treatment for form of MS approved by FDA
March 30, 2017Sales and Marketing Biogen, Genentech, MS, Roche
In big news for sufferers of MS and the company that developed the drug, Roche subsidiary Genetech, the FDA has …
Genentech plans second Phase 3 Alzheimer’s trial following endpoint failures
March 20, 2017Research and Development, Sales and Marketing Alzheimer's, Genentech, Roche
Genentech, Roche’s biotech group, has announced its plans to conduct a second Phase 3 study for crenezumab, its anti-Abeta antibody …
Mylan’s pathway to launch of biosimilar to Herceptin cleared by Roche
March 13, 2017Manufacturing and Production, Sales and Marketing Genentech, Herceptin, Mylan, Roche, biosimilar
Mylan scored a big victory in its plan to launch its biosimilar to Roche’s blockbuster, Herceptin, after Roche and itself …
Immunotherapy: The three major treatments that are changing cancer prognoses
March 13, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Cancer, MSD, Roche, immunotherapy, keytruda, oncology, opdivo, tecentriq
The promise of Immunotherapy as a game-changer for cancer treatment has been evident since its advent in the space. However, …
Roche’s neoadjuvant breast cancer combo therapy shows strong Phase 3 results
March 2, 2017Research and Development Herceptin, Perjeta, Roche
Roche’s combination treatment of Perjeta (pertuzumab), Herceptin (trasdtuzumab) and chemotherapy met its primary endpoint in a recent Phase 3 study. …
Death in trial of Roche’s potential blockbuster haemophilia drug
February 24, 2017Medical Communications, Research and Development Novo Nordisk, Roche, Shire, haemophilia
Roche has reported a death in the trial of its haemophilia treatment, emicizumab, that will only add to safety concerns …
Roche and Discuva extend agreement to develop target antimicrobials
February 22, 2017Research and Development, Sales and Marketing Discuva, Roche
Discuva, a drug discovery company based in Cambridge, UK, has announced that its collaboration with Roche, first agreed in 2014, …
The March 2017 issue of Pharmafocus is now live!
February 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actelion, FDA, Johnson & Johnson, MSD, Roche, Trump, crispr, immunotherapy, opdivo
The latest edition of Pharmafocus is available to read online now! From breakthroughs in antibiotic resistance R&D to gene editing …
Genentech oncology head leaves for Bellicum CEO role
February 1, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bellicum, Genentech, Roche, tecentriq
Bellicum Pharmaceuticals has snatched up Genentech’s Rick Fair as its new CEO and President. Fair moves to Bellicum from Genentech …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
